Français
France
s'inscrire
Conseils d'eurolivre.fr
Livres similaires
Autres livres qui pourraient ressembler au livre recherché:
Outils de recherche
Livre conseillé
Actualités
Publicité
FILTRE
- 0 Résultats
prix le plus bas: 117,66 €, prix le plus élevé: 245,03 €, prix moyen: 156,61 €
Fluoropyrimidines in Cancer Therapy - Youcef M. Rustum
Livre non disponible
(*)
Youcef M. Rustum:
Fluoropyrimidines in Cancer Therapy - edition reliée, livre de poche

ISBN: 0896039560

ID: 4172259175

[EAN: 9780896039568], Neubuch, This hard cover print on demand book can incur an additional 1-2 working days handling time on top of the regular 2-3 working day delivery for UK standard delivery. Please note expedited shipping does not accelerate delivery times for print on demand books. We ship using Royal Mail or courier in the UK and Europe with tracking number for heavier or more valuable items. All USA orders have a shipment tracking number.Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on its Cytotoxic Effects: Preclinical and Clinical Modulation G. J. Peters Dihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines: Past and Future Directions Gà rard Milano Biochemical Bases of the 5-Fluorouracil-Folinic Acid Interaction and of its Limitations: A Retrospective Analysis Richard G. Moran Molecular Mechanisms Regulating the Expression of Thymidylate Synthase John C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, and Edward Chu Regulation of Thymidylate Synthase Gene Expression and Drug Response: Posttranscriptional Regulation and Cell Population Density Bruce J. Dolnick Death Receptor Signaling in the Mechanism of 5-Fluorouracil Action Janet A. Houghton Circadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic Applications Francis Là vi Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents Alberto F. Sobrero and Ornella Belvedere Noninvasive Studies of Fluoropyrimidines Walter Wolf, Cary A. Presant, and Victor Waluch Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: Role of Leucovorin and Dihydropyrimidine Dehydrogenase Inhibitors Shousong Cao, Gunnar Hapke, and Youcef M. Rustum Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer Aimery de Gramont and Christophe Louvet Review on the Combination of Systemic and Locoregional Treatment for Colorectal Liver Metastases Roberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti, and M. Adelaide Pessi Fluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-Analyses Pascal Piedbois and Marc E. Buyse The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer Charles Erlichman, Richard M. Goldberg, and Daniel J. Sargent Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: The NSABP Experience Roy E. Smith, Eleftherios P. Mamounas, and Norman Wolmark Clinical Trials of UFT Leucovorin in Gastrointestinal Malignancies Paulo M. Hoff and Everardo D. Saad The Development of Oral UFT with and without Leucovorin Geert H. Blijham UFT in Elderly Patients with Colorectal Cancer Albert Abad and Josà Luis Manzano Clinical Trials of the Eniluracil/5-Fluorouracil Combination Hedy L. Kindler and Richard L. Schilsky Discovery and Preclinical Pharmacology of Capecitabine Hideo Ishitsuka Capecitabine, A Tumor-Targeting Oral Fluoropyrimidine: Molecular Rationale and Clinical Validation Dvorit Samid Capecitabine: A Rationally Developed Anticancer Drug Daniel R. Budman Preclinical and Clinical Practice of S-1 in Japan Tetsuhiko Shirasaka and Tetsuo Taguchi Preclinical and Clinical Practice of Low-Dose FP Therapy in Japan: Japanese Use of Low-Dose FP Therapy Tetsuhiko Shirasaka, Akihito Tsuji, Susumu Yam. Brand NEW unread book. This

Nouveaux livres Abebooks.de
Books Express (Academic & Professional), Saffron Walden, ESS, United Kingdom [53379852] [Rating: 5]
NEW BOOK Frais d'envoi EUR 3.37
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.
Fluoropyrimidines in Cancer Therapy - Youcef M. Rustum
Livre non disponible
(*)
Youcef M. Rustum:
Fluoropyrimidines in Cancer Therapy - nouveau livre

ISBN: 0896039560

ID: 4172259175

[EAN: 9780896039568], Neubuch, Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on its Cytotoxic Effects: Preclinical and Clinical Modulation G. J. Peters Dihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines: Past and Future Directions Gà rard Milano Biochemical Bases of the 5-Fluorouracil-Folinic Acid Interaction and of its Limitations: A Retrospective Analysis Richard G. Moran Molecular Mechanisms Regulating the Expression of Thymidylate Synthase John C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, and Edward Chu Regulation of Thymidylate Synthase Gene Expression and Drug Response: Posttranscriptional Regulation and Cell Population Density Bruce J. Dolnick Death Receptor Signaling in the Mechanism of 5-Fluorouracil Action Janet A. Houghton Circadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic Applications Francis Là vi Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents Alberto F. Sobrero and Ornella Belvedere Noninvasive Studies of Fluoropyrimidines Walter Wolf, Cary A. Presant, and Victor Waluch Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: Role of Leucovorin and Dihydropyrimidine Dehydrogenase Inhibitors Shousong Cao, Gunnar Hapke, and Youcef M. Rustum Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer Aimery de Gramont and Christophe Louvet Review on the Combination of Systemic and Locoregional Treatment for Colorectal Liver Metastases Roberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti, and M. Adelaide Pessi Fluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-Analyses Pascal Piedbois and Marc E. Buyse The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer Charles Erlichman, Richard M. Goldberg, and Daniel J. Sargent Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: The NSABP Experience Roy E. Smith, Eleftherios P. Mamounas, and Norman Wolmark Clinical Trials of UFT Leucovorin in Gastrointestinal Malignancies Paulo M. Hoff and Everardo D. Saad The Development of Oral UFT with and without Leucovorin Geert H. Blijham UFT in Elderly Patients with Colorectal Cancer Albert Abad and Josà Luis Manzano Clinical Trials of the Eniluracil/5-Fluorouracil Combination Hedy L. Kindler and Richard L. Schilsky Discovery and Preclinical Pharmacology of Capecitabine Hideo Ishitsuka Capecitabine, A Tumor-Targeting Oral Fluoropyrimidine: Molecular Rationale and Clinical Validation Dvorit Samid Capecitabine: A Rationally Developed Anticancer Drug Daniel R. Budman Preclinical and Clinical Practice of S-1 in Japan Tetsuhiko Shirasaka and Tetsuo Taguchi Preclinical and Clinical Practice of Low-Dose FP Therapy in Japan: Japanese Use of Low-Dose FP Therapy Tetsuhiko Shirasaka, Akihito Tsuji, Susumu Yamamitsu, and Tetsuo Taguchi Brand NEW unread book. This item is printed on demand. Perfectly bound book in mint condition.

Nouveaux livres Abebooks.de
Books Express (Academic & Professional), Saffron Walden, ESS, United Kingdom [53379852] [Rating: 5 (von 5)]
NEW BOOK Frais d'envoi EUR 5.99
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.
Fluoropyrimidines in Cancer Therapy
Livre non disponible
(*)
Fluoropyrimidines in Cancer Therapy - edition reliée, livre de poche

2002, ISBN: 0896039560, Lieferbar binnen 4-6 Wochen Frais d'envoiVersandkostenfrei innerhalb der BRD

ID: 9780896039568

Internationaler Buchtitel. In englischer Sprache. Verlag: Springer-Verlag GmbH, HC runder Rücken kaschiert, 340 Seiten, L=254mm, B=178mm, H=23mm, Gew.=833gr, [GR: 16960 - HC/Medizin/Andere Fachgebiete], Gebunden, Klappentext: Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents. Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

Nouveaux livres DEU
Buchgeier.com
Lieferbar binnen 4-6 Wochen (Besorgungstitel) Frais d'envoiVersandkostenfrei innerhalb der BRD
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.
Fluoro-Pyrimidines in Cancer Therapy - Youcef M. Rustum
Livre non disponible
(*)
Youcef M. Rustum:
Fluoro-Pyrimidines in Cancer Therapy - edition reliée, livre de poche

2002, ISBN: 9780896039568

ID: 4405441

Hardcover, Buch, [PU: Humana Press Inc.]

Nouveaux livres Lehmanns.de
Frais d'envoiVersand in 7-9 Tagen, , Sans frais d'envoi en Allemagne (EUR 0.00)
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.

Détails sur le livre
Fluoropyrimidines in Cancer Therapy

Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

Informations détaillées sur le livre - Fluoropyrimidines in Cancer Therapy


EAN (ISBN-13): 9780896039568
ISBN (ISBN-10): 0896039560
Version reliée
Date de parution: 2002
Editeur: Springer-Verlag GmbH
340 Pages
Poids: 0,833 kg
Langue: eng/Englisch

Livre dans la base de données depuis 29.08.2007 16:37:22
Livre trouvé récemment le 18.12.2016 19:37:34
ISBN/EAN: 9780896039568

ISBN - Autres types d'écriture:
0-89603-956-0, 978-0-89603-956-8


< pour archiver...
Livres en relation